FDA Extends Ruxolitinib Cream Review Period for Pediatric AD ...Middle East

Medscape - News
FDA Extends Ruxolitinib Cream Review Period for Pediatric AD
The supplemental application is based on data from a phase 3 study of children aged 2-12 years with mild-to-moderate AD, randomly assigned to 0.75% or 1.5% ruxolitinib or a vehicle. Medscape Medical News

Hence then, the article about fda extends ruxolitinib cream review period for pediatric ad was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Extends Ruxolitinib Cream Review Period for Pediatric AD )

Apple Storegoogle play

Last updated :

Also on site :